• Recruiting

NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - MajesTEC-3

Updated: Sep 16

MajesTEC-3


A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3)


64007957MMY3001

MajesTEC-3 MYELOMA TRIAL

NCT05083169: A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3)

Relapsed & Refractory Multiple Myeloma


The purpose of this study is to compare the efficacy of teclistamab-daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd) or daratumumab SC in combination with bortezomib and dexamethasone (DVd).

 

Sponsor

Janssen Research & Development, LLC


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT05083169

Official Title: A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

First Posted : October 19, 2021

Click here to see details on ClinicalTrials.gov


A Study of Teclistamab in Combination with Daratumumab Subcutaneously (SC) (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants with Relapsed or Refractory Multip... | Global Trial Finder (janssen.com)

 

JNJ 64007957 - Teclistamab

 

Drug: Daratumumab ( Darzalex)

Drug: Pomalidomide ( Pomalyst)

Drug: Dexamethasone ( Decadron)

Drug: Bortezomib ( Velcade)

Drug: Teclistamab

 

- Alabama: University of Alabama at Birmingham

- California: City of Hope Duarte

- Connecticut: Yale University New Haven

- Minnesota: Mayo Clinic Rochester Minnesota

- New Jersey: Hackensack University Medical Center

- Ohio: Cleveland Clinic Ohio

- Pennsylvania: University of Pittsburgh Medical Center

- Texas: UT Southwestern Medical Center Dallas

- Washington: Seattle Cancer Care Alliance

- Wisconsin: Medical College of Wisconsin Milwaukee

 

Locations

United States, Alabama

United States, California

United States, Connecticut

United States, Georgia

United States, Massachusetts

United States, Michigan

United States, Minnesota

United States, New Jersey

United States, New York

United States, Ohio

United States, Oregon

United States, Pennsylvania

United States, South Carolina

United States, Tennessee

United States, Texas

United States, Utah

United States, Washington

United States, Wisconsin


Canada

Canada, Alberta

Canada, British Columbia

Canada, Nova Scotia

Canada, Ontario

Canada, Quebec


Argentina

Brazil


China


Europe

United Kingdom

France

Germany

Italy

Netherlands

Spain

Belgium

Denmark

Greece

Poland

Sweden


Asia

Japan

Korea, Republic of

Russian Federation

Taiwan

 

RELATED POSTS


TECLISTAMAB STUDIES:


NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma (MajesTEC1)

Click here for details


NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)

Click here for details


NCT05243797: Phase 3: Tec + Len Vs Len Alone in NDMM as Maintenance Therapy Post ASCT (MajesTEC-4)

Click here for details


NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma

Click here for details


NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)

Click here for details

 

TALQUETAMAB STUDIES:


NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1

Click here for details


NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma

Click here for details


NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma

Click here for details


NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma

Click here for details

 

TECLISTAMAB AND TALQUETAMAB STUDIES:


NCT04586426: Phase 1b - Talquetamab and Teclistamab in Relapsed or Refractory Multiple Myeloma

Click here for details


NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2

Click here for details







Posts Archive